← Back to Briefing
Non-Opioid Painkiller Developer Latigo Therapeutics Seeks $288 Million US IPO
Importance: 45/1001 Sources
Why It Matters
This IPO reflects growing investor confidence in non-addictive pain management solutions, which could revolutionize treatment for chronic pain and reduce reliance on opioids.
Key Intelligence
- ■Latigo Therapeutics, a biotech company specializing in non-opioid pain treatments, is planning a US Initial Public Offering (IPO).
- ■The company aims to raise $288 million through its market debut.
- ■The capital sought will fund the development and advancement of its non-opioid painkiller pipeline.